JP6946353B2 - ５′−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 - Google Patents

５′−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 Download PDF

Info

Publication number
JP6946353B2
JP6946353B2 JP2018563379A JP2018563379A JP6946353B2 JP 6946353 B2 JP6946353 B2 JP 6946353B2 JP 2018563379 A JP2018563379 A JP 2018563379A JP 2018563379 A JP2018563379 A JP 2018563379A JP 6946353 B2 JP6946353 B2 JP 6946353B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
adpr
composition according
disease
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505596A5 (https=
JP2019505596A (ja
Inventor
シャルウィッツ ロバート
シャルウィッツ ロバート
Original Assignee
インバーサ， インコーポレイテッド
インバーサ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インバーサ， インコーポレイテッド, インバーサ， インコーポレイテッド filed Critical インバーサ， インコーポレイテッド
Publication of JP2019505596A publication Critical patent/JP2019505596A/ja
Publication of JP2019505596A5 publication Critical patent/JP2019505596A5/ja
Priority to JP2021149881A priority Critical patent/JP7222042B2/ja
Application granted granted Critical
Publication of JP6946353B2 publication Critical patent/JP6946353B2/ja
Priority to JP2023014497A priority patent/JP7600282B2/ja
Priority to JP2024210859A priority patent/JP2025032189A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
JP2018563379A 2016-02-18 2017-02-17 ５′−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 Active JP6946353B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021149881A JP7222042B2 (ja) 2016-02-18 2021-09-15 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2023014497A JP7600282B2 (ja) 2016-02-18 2023-02-02 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2024210859A JP2025032189A (ja) 2016-02-18 2024-12-04 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662296665P 2016-02-18 2016-02-18
US62/296,665 2016-02-18
US201662428721P 2016-12-01 2016-12-01
US62/428,721 2016-12-01
PCT/US2017/018253 WO2017143113A1 (en) 2016-02-18 2017-02-17 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021149881A Division JP7222042B2 (ja) 2016-02-18 2021-09-15 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Publications (3)

Publication Number Publication Date
JP2019505596A JP2019505596A (ja) 2019-02-28
JP2019505596A5 JP2019505596A5 (https=) 2020-04-02
JP6946353B2 true JP6946353B2 (ja) 2021-10-06

Family

ID=58191671

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018563379A Active JP6946353B2 (ja) 2016-02-18 2017-02-17 ５′−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2021149881A Active JP7222042B2 (ja) 2016-02-18 2021-09-15 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2023014497A Active JP7600282B2 (ja) 2016-02-18 2023-02-02 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2024210859A Pending JP2025032189A (ja) 2016-02-18 2024-12-04 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021149881A Active JP7222042B2 (ja) 2016-02-18 2021-09-15 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2023014497A Active JP7600282B2 (ja) 2016-02-18 2023-02-02 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2024210859A Pending JP2025032189A (ja) 2016-02-18 2024-12-04 ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Country Status (16)

Country Link
US (3) US11110112B2 (https=)
EP (2) EP3416654B1 (https=)
JP (4) JP6946353B2 (https=)
KR (2) KR102622656B1 (https=)
CN (2) CN108601793B (https=)
AU (2) AU2017219878B2 (https=)
BR (1) BR112018016398A2 (https=)
DK (1) DK3416654T3 (https=)
ES (1) ES2900524T3 (https=)
HR (1) HRP20211942T1 (https=)
HU (1) HUE057052T2 (https=)
IL (2) IL291574B2 (https=)
LT (1) LT3416654T (https=)
PL (1) PL3416654T3 (https=)
PT (1) PT3416654T (https=)
WO (1) WO2017143113A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
WO2019191026A2 (en) * 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
KR102789553B1 (ko) * 2021-09-07 2025-04-03 주식회사 펄스인마이어스 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
EP4509133A4 (en) * 2023-03-02 2026-03-25 Pearlsinmires Co Ltd ADP-RIBOSE BINDING PEPTIDE FOR CANCER PREVENTION OR TREATMENT, AND ADP-RIBOSE POLYTHERAPY
WO2026073064A1 (en) * 2024-09-30 2026-04-02 Invirsa, Inc. 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (ja) 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
JP2001515916A (ja) * 1997-09-11 2001-09-25 オクシジェン，インコーポレイテッド 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法
WO2000050024A2 (en) 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
EP1192258A2 (en) 1999-06-16 2002-04-03 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
EP1409503A1 (en) 2001-07-25 2004-04-21 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
AU2003230952A1 (en) 2002-05-21 2003-12-12 Abbott Laboratories Treatment of mucositis
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050276762A1 (en) 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1948215B1 (en) 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
WO2008154129A1 (en) 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
JP2013526514A (ja) 2010-05-10 2013-06-24 ラディカル・セラピューティックス・インコーポレイテッド リポ酸およびニトロキシド誘導体およびその使用
KR101967938B1 (ko) 2011-05-12 2019-04-10 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물
US20160287622A1 (en) 2013-11-18 2016-10-06 Massachusetts Institute Of Technology Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Also Published As

Publication number Publication date
IL291574A (en) 2022-05-01
AU2017219878B2 (en) 2022-12-22
JP2025032189A (ja) 2025-03-11
US20220054522A1 (en) 2022-02-24
IL291574B1 (en) 2025-01-01
IL291574B2 (en) 2025-05-01
KR102622656B1 (ko) 2024-01-10
KR20230148389A (ko) 2023-10-24
IL261095B (en) 2022-04-01
JP7222042B2 (ja) 2023-02-14
JP2021193126A (ja) 2021-12-23
US11110112B2 (en) 2021-09-07
US20200330498A1 (en) 2020-10-22
CN108601793A (zh) 2018-09-28
AU2023201678B2 (en) 2025-03-13
KR102883682B1 (ko) 2025-11-10
LT3416654T (lt) 2022-01-10
JP2023055858A (ja) 2023-04-18
BR112018016398A2 (pt) 2018-12-18
ES2900524T3 (es) 2022-03-17
US12370209B2 (en) 2025-07-29
US20240091249A1 (en) 2024-03-21
US11857561B2 (en) 2024-01-02
CA3014071A1 (en) 2017-08-24
EP3978003A1 (en) 2022-04-06
HRP20211942T1 (hr) 2022-03-18
JP2019505596A (ja) 2019-02-28
JP7600282B2 (ja) 2024-12-16
HUE057052T2 (hu) 2022-04-28
AU2017219878A1 (en) 2018-08-09
EP3416654A1 (en) 2018-12-26
DK3416654T3 (da) 2021-12-13
AU2023201678A1 (en) 2023-04-13
CN117482102A (zh) 2024-02-02
IL261095A (en) 2018-10-31
EP3416654B1 (en) 2021-10-27
CN108601793B (zh) 2024-08-23
PL3416654T3 (pl) 2022-03-21
PT3416654T (pt) 2021-12-22
WO2017143113A1 (en) 2017-08-24
KR20180111841A (ko) 2018-10-11

Similar Documents

Publication Publication Date Title
JP7222042B2 (ja) ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP7745584B2 (ja) ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
TWI842679B (zh) 含有吡啶基胺乙酸化合物之醫藥
WO2025122455A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr) for vegf modulation
TW304879B (https=)
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40073052A (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
HK1263210B (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
WO2025135087A1 (ja) 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物
CN101759741B (zh) 一种化合物及其在制备治疗血管新生的药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210915

R150 Certificate of patent or registration of utility model

Ref document number: 6946353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250